# Contributors

# AUTHORS

## ESTEBAN CELIS, MD, PhD

Department of Medicine, Medical College of Georgia, Scientific Consultant, Oncovir, Inc, Augusta, Georgia

### AVERY DAVIS, MD

The Department of Urology, Icahn School of Medicine at Mount Sinai, New York, New York, USA

### ZACHARY DOVEY, BSc, MBBS

Department of Urology, Icahn School of Medicine at Mount Sinai, New York, New York

#### SUJIT S. NAIR, PhD

Assistant Professor, Director of GU Immunotherapy Research, Department of Urology, Icahn School of Medicine at Mount Sinai, New York, New York

## TATIANA OMELCHENKO, PhD

Senior Research Scientist, Cell Biology Program, Sloan Kettering Institute at Memorial Sloan Kettering Cancer Center, New York, New York

#### BORIS A. REVA, PhD

Associate Professor, Director of Oncology Sequence Informatics, Department of Genetics and Genomic Sciences, Icahn School of Medicine at Mount Sinai, New York, New York

#### ANDRES M. SALAZAR, MD

Founder, CEO, and Scientific Director, Oncovir, Inc, Washington, DC

# ASHUTOSH K. TEWARI, MBBS, MCh, FRCS (Hon)

Professor and System Chair, The Milton and Carroll Petrie Department of Urology, Director, Center of Excellence for Prostate Cancer at the Tisch Cancer Institute, Mount Sinai Health System, Icahn School of Medicine at Mount Sinai, New York, New York

### RACHEL WEIL, MD

The Department of Urology, Icahn School of Medicine at Mount Sinai, New York, New York